ATF-3 expression inhibits melanoma growth by downregulating ERK and AKT pathways

Lab Invest. 2021 May;101(5):636-647. doi: 10.1038/s41374-020-00516-y. Epub 2020 Dec 9.

Abstract

Activating transcription factor 3 (ATF-3), a cyclic AMP-dependent transcription factor, has been shown to play a regulatory role in melanoma, although its function during tumor progression remains unclear. Here, we demonstrate that ATF-3 exhibits tumor suppressive function in melanoma. Specifically, ATF-3 nuclear expression was significantly diminished with melanoma progression from nevi to primary to metastatic patient melanomas, correlating low expression with poor prognosis. Significantly low expression of ATF-3 was also found in cultured human metastatic melanoma cell lines. Importantly, overexpression of ATF-3 in metastatic melanoma cell lines significantly inhibited cell growth, migration, and invasion in vitro; as well as abrogated tumor growth in a human melanoma xenograft mouse model in vivo. RNA sequencing analysis revealed downregulation of ERK and AKT pathways and upregulation in apoptotic-related genes in ATF-3 overexpressed melanoma cell lines, which was further validated by Western-blot analysis. In summary, this study demonstrated that diminished ATF-3 expression is associated with melanoma virulence and thus provides a potential target for novel therapies and prognostic biomarker applications.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Activating Transcription Factor 3 / metabolism*
  • Animals
  • Apoptosis
  • Female
  • Humans
  • MAP Kinase Signaling System
  • Melanoma / metabolism*
  • Melanoma, Experimental / metabolism
  • Mice
  • Mice, Nude
  • Oncogene Protein v-akt / metabolism
  • Phosphorylation
  • Retrospective Studies

Substances

  • ATF3 protein, human
  • Activating Transcription Factor 3
  • Oncogene Protein v-akt